A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage
Latest Information Update: 13 Nov 2025
At a glance
- Drugs Blinatumomab (Primary) ; Pembrolizumab (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 10 Nov 2025 Status changed from active, no longer recruiting to completed.
- 28 Aug 2023 Planned End Date changed from 1 Aug 2023 to 31 Dec 2025.
- 28 Aug 2023 Planned primary completion date changed from 1 Aug 2022 to 31 Dec 2025.